uniQure N.V. - Ordinary Shares — Bilan (NASDAQ:QURE)

Afficher le graphique complet Full chart

Financials

Total de l'actif 340.39 M809.18 M704.96 M831.69 M556.54 M824.91 M Total du passif 96.49 M213.4 M228.96 M624.02 M563.29 M626.01 M Total des capitaux propres 243.91 M595.78 M476.01 M207.67 M-6.75 M198.9 M Total du passif et des capitaux propres 340.39 M809.18 M704.96 M831.69 M556.54 M824.91 M Dette totale 35.62 M100.96 M102.79 M101.75 M51.32 M49.7 M Dette nette 35.62 M100.96 M102.79 M101.75 M51.32 M-573.15 M

uniQure N.V. - Ordinary Shares

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

QURE

Financials

uniQure N.V. - Ordinary Shares

Nouvelles

Le titre d’uniQure bondit de 20 % après l’annonce de Replimune sur la FDA

Biotech Investors Are Tuning Out the MAHA Chaos

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure prévoit un dépôt au Royaume-Uni pour la thérapie génique AMT-130 contre la maladie de Huntington

Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Mizuho relève la note d’uniQure suite au changement à la FDA

Mizuho upgrades uniQure stock rating on FDA leadership change